MUMBAI, Oct. 6, 2022 /PRNewswire/ — Alkem Laboratories Limited, the 5th largest Indian pharmaceutical firm, has launched for the first time in India, triple drug mounted dose mixture (FDC) of Dapagliflozin, Sitagliptin and Metformin beneath the model identify of Dapanorm Trio® at an inexpensive worth for adults with Type 2 Diabetes in India.
Speaking on the launch of Dapanorm Trio®, Mr. Mohammed Musarif Pasha, Associate Vice President (Sales & Marketing), Alkem stated “Alkem’s Dapanorm Trio® will have a significant role in reducing HbA1c in uncontrolled type 2 diabetic patients & will help to improve patient compliance by reducing pill burden as well as medical bill burden. It will help the doctors to achieve good glycemic control in their patients. Dapanorm Trio® has additional advantages like the lowest risk of hypoglycemia, better pancreatic beta cell protection, cardiac and renal benefits with better tolerability among elderly diabetic patients.”
In the multidisciplinary administration of kind 2 Diabetes, sufferers must devour a number of capsules for longer length in order to realize efficient management of blood glucose. Mr. Pasha additional added, “Majority of patients in Rs19.70 per tablet which is almost 70% less compared to the combined cost of innovator drugs.”
Alkem obtained advertising and marketing authorization for Dapanorm Trio® FDCs based mostly on a section III multicentric, randomized, double blind scientific trial (MESIDA trial) which in contrast the efficacy of triple drug FDC of Dapagliflozin, sitagliptin and metformin vs mixture of Sitagliptin and metformin. The examine was performed in 274 sufferers of kind 2 Diabetes throughout India. The outcome of scientific trial confirmed that triple drug FDC Dapanorm Trio® had superior efficacy in phrases of glycemic management as in comparison with twin drug mixture.
About Alkem Laboratories Limited
Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a number one Indian pharmaceutical firm with international operations, engaged in the event, manufacture and sale of pharmaceutical and nutraceutical merchandise. The Company produces branded generics, generic medicine, lively pharmaceutical elements (APis) and nutraceuticals, which it markets in India and International markets. With a portfolio of greater than 800 manufacturers in India, Alkem is ranked the fifth largest pharmaceutical firm in India in phrases of home gross sales (Source: IQVIA March 2021). The Company additionally has presence in greater than 40 worldwide markets, with the United States being its key focus market.
For extra data on Alkem Laboratories Ltd., please go to www.alkemlabs.com
Logo – https://mma.prnewswire.com/media/1915343/Alkem_Laboratories_Logo.jpg
